Paul F. Schellhammer, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Eastern Virginia Medical School Of The Medical College Of Hampton Roads - Norfolk VA
Rank: Full Professor
Years: 1974-2001

Eastern Virginia Medical School Of The Medical College Of Hampton Roads - Norfolk VA
Rank: Full Professor
Years: 1974-present

Eastern Virginia Medical School Of The Medical College Of Hampton Roads - Norfolk VA
Rank: Full Professor
Years: 1990-present

None Reported

Should we delay prostate radiotherapy?
J Clin Oncol
Volume: 17(4)
Date: 04 1999

Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer
Clin Cancer Res
Volume: 5(12)
Date: 12 1999

Ultrasound-guided brachytherapy: is it really better?
Urology
Volume: 55(2)
Date: 02 2000

Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
Urology
Volume: 55(3)
Date: 03 2000

Outcomes after intravesicle bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma
J Urol
Volume: 163(4)
Date: 04 2000

The prognostic signifiance of S-phase analysis in stage T1/T1 bladder cancer - Southwest Oncology Group
Eur Urol
Volume: 37(5)
Date: 05 2000

Treament planning for clinically localized prostate cancer
Radiology
215 Suppl
Date: 06 2000

Fifteen-year minimal follow-up of a prostate brachytheapy series: comparing the past with the present
Urology
Volume: 56(3)
Date: 09 2000

Overexpressiong of p53 in prostate carcinoma is associated with improved overall surgical but not predictive of response to radiotherapy
Int J Oncol
Volume: 17(4)
Date: 10 2000

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy study
J Urol
Volume: 163(1)
Date: 01 2012